Catalog No.A2013 Synonyms: MEDI4736 Non-humanized mouse model applicable
For research use only. Not for use in humans.
Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.
Choose Selective PD-1/PD-L1 Inhibitors
|Description||Durvalumab is a selective, high affinity human IgG1 mAb that blocks programmed cell death ligand-1 (PD-L1) binding to PD-1 (IC50=0.1 nM) and CD80 (IC50=0.04 nM). MW=146.3 kDa.|
MEDI4736 is a potent antagonist of PD-L1 function, blocking interaction with PD-1 and CD80 to overcome inhibition of primary human T-cell activation. It does not trigger antibody-dependent cellular cytotoxicity (ADCC).
|In vivo||In vivo MEDI4736 significantly inhibits the growth of human tumors in a novel xenograft model containing coimplanted human T cells. In patients with advanced solid tumors, The linear clearance, volume of distribution and concentration at half maximal elimination (KM) of MEDI4736 are 240 mL/day, 3.6 L and 0.4 μg/mL, respectively. The half-life is ~23 days at doses ≥ 3 mg/kg Q2W. Greater than 99% target saturation (soluble and membrane bound) is expected at ≥40 μg/mL of MEDI4736.|
|Formulation||PBS buffer, pH 7.2|
|Storage||Store at -80°C and avoid freeze-thaw cycles.|
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT03519971||Recruiting||Non-Small Cell Lung Cancer||AstraZeneca||April 9 2018||Phase 3|
|NCT03405454||Recruiting||Ovarian Clear Cell Carcinoma||National University Hospital Singapore||October 9 2017||Phase 2|
|NCT02369874||Active not recruiting||Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN||AstraZeneca||September 9 2015||Phase 3|
|NCT02273375||Recruiting||Non-Small Cell Lung Cancer||Canadian Cancer Trials Group|Intergroupe Francophone de Cancerologie Thoracique (IFCT)|Australasian Lung Cancer Trials Group|National Health and Medical Research Council Australia|National Cancer Institute (NCI) Naples|Central and Eastern European Oncology Group|Dutch Society of Physicians for Pulmonology and Tuberculosis|Korean Cancer Study Group|Spanish Lung Cancer Group|West Japan Oncology Group (WJOG)|Chinese Thoracic Oncology Group||October 9 2014||Phase 3|
|NCT03376659||Recruiting||Metastatic Colorectal Cancer|Colorectal Adenocarcinoma|Pancreatic Adenocarcinoma|Metastatic Pancreatic Cancer||Georgetown University|Mayo Clinic|Indiana University|Emory University|National Cancer Institute (NCI)|George Mason University|Thomas Jefferson University|MedImmune LLC|Bavarian Nordic Inc.||August 8 2018||Phase 1|Phase 2|
|NCT03011814||Recruiting||Folliculotropic Mycosis Fungoides|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Peripheral T-Cell Lymphoma Not Otherwise Specified|Sezary Syndrome|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma||City of Hope Medical Center|National Cancer Institute (NCI)||March 8 2017||Phase 1|Phase 2|
If you have any other enquiries, please leave a message.